Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04797780 · ClinicalTrials.gov registry record · Phase 3
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
A Phase 3 study, sponsored by Syros Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 246
- Enrollment target
NCT04797780 is a Phase 3 study that was terminated before completion, run by Syros Pharmaceuticals. The registered enrollment target is 246 participants.
The verdict
NCT04797780, a Phase 3 study, was terminated before completion, sponsored by Syros Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 246 participants
- Enrollment target
Study Summary
This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.
Interventions
- DRUG Placebo
- DRUG Azacitidine
- DRUG Tamibarotene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2021-02-08 |
| Est. Completion | 2024-11-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04797780
The ClinicalTrials.gov registry entry for NCT04797780 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syros Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04797780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04797780 about?
NCT04797780 is a clinical study titled "Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome". This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatmen...
What is the current status of trial NCT04797780?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 246 participants. The study started on 2021-02-08. Estimated completion is 2024-11-13.
What interventions are being tested in trial NCT04797780?
The interventions under investigation include: Placebo (DRUG), Azacitidine (DRUG), Tamibarotene (DRUG).
Who is sponsoring clinical trial NCT04797780?
This trial is sponsored by Syros Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.